Screening & Prevention — MCQs
On this page
A 55-year-old man attends for NHS Health Check. He has a BMI of 31 kg/m², BP 138/86 mmHg, and is a non-smoker. Blood tests show HbA1c 43 mmol/mol (non-diabetic range), total cholesterol 5.4 mmol/L, and HDL 0.9 mmol/L. His QRISK3 score is 16%. He works night shifts as a warehouse supervisor and admits to poor sleep quality, often sleeping only 4-5 hours daily. Recent research suggests chronic sleep deprivation is associated with increased cardiovascular risk. How should this information influence his management?
A 44-year-old woman attends requesting advice about breast screening. Her sister was recently diagnosed with breast cancer aged 47. Her mother had ovarian cancer aged 52 and died from it. The patient herself is well with no symptoms. She asks when she should start having mammograms. What is the most appropriate initial management?
A 68-year-old man with a 4.7 cm infrarenal abdominal aortic aneurysm (AAA) detected through NHS screening attends for discussion. He has been under surveillance with 3-monthly scans for 18 months. The most recent scan shows the aneurysm has increased from 4.5 cm to 4.7 cm over the past 3 months. He is asymptomatic. He has COPD with FEV1 65% predicted, type 2 diabetes, and hypertension. He quit smoking 2 years ago. What is the most appropriate management?
A 33-year-old woman attends with her cervical screening result showing hrHPV positive with low-grade dyskaryosis. She underwent colposcopy 6 months ago for similar results, and punch biopsy at that time showed CIN1. The colposcopist advised repeat cytology in 6 months, which is the current result. She has no symptoms and is currently 8 weeks pregnant. What is the most appropriate next step in management?
A 70-year-old woman attends for cardiovascular risk assessment. She has a BMI of 27 kg/m² and walks her dog daily for 30 minutes. She does not smoke and drinks 6 units of alcohol weekly. Blood tests show total cholesterol 6.8 mmol/L, HDL 1.6 mmol/L, and HbA1c 41 mmol/mol. Her BP is 126/76 mmHg. She asks about starting a statin as her friend was prescribed one. Her QRISK3 score is 8%. What is the most appropriate management?
A 56-year-old woman with type 2 diabetes for 12 years attends for annual review. Her HbA1c is 64 mmol/mol. She mentions she received a letter about diabetic eye screening but has not attended for the past 2 years as she has 'perfect vision' and sees no point in screening. Her visual acuity today is 6/6 bilaterally. What is the most important reason to emphasise the need for diabetic retinopathy screening?
A 61-year-old woman attends following her NHS bowel cancer screening. Her FIT result is 78 μg Hb/g faeces. She has no symptoms, no weight loss, and bowel habit is unchanged. Abdominal examination is normal. She has a history of diverticular disease diagnosed 3 years ago. She takes amlodipine for hypertension. What is the most appropriate next management step?
A 47-year-old man attends for advice about reducing his cardiovascular risk. He has a BMI of 32 kg/m², smokes 20 cigarettes daily, and drinks 28 units of alcohol weekly. His BP is 144/88 mmHg. His 10-year QRISK3 score is 18%. He is keen to make lifestyle changes but feels overwhelmed about where to start. Based on evidence for cardiovascular risk reduction, which intervention should be prioritised?
What is the screening interval for NHS breast screening for women aged 50-70 years in England?
A 28-year-old woman attends with her cervical screening result. She is nulliparous and has been in a monogamous relationship for 2 years. The hrHPV test is positive, but cytology shows normal cells (hrHPV positive, cytology negative). She has no symptoms and examination is normal. She is anxious about the result and asks about the likelihood of developing cervical cancer. What is the most appropriate next management step?
Screening & Prevention UK Medical PG Practice Questions and MCQs
Question 11: A 55-year-old man attends for NHS Health Check. He has a BMI of 31 kg/m², BP 138/86 mmHg, and is a non-smoker. Blood tests show HbA1c 43 mmol/mol (non-diabetic range), total cholesterol 5.4 mmol/L, and HDL 0.9 mmol/L. His QRISK3 score is 16%. He works night shifts as a warehouse supervisor and admits to poor sleep quality, often sleeping only 4-5 hours daily. Recent research suggests chronic sleep deprivation is associated with increased cardiovascular risk. How should this information influence his management?
- A. Sleep duration is not an established modifiable cardiovascular risk factor in current guidelines and should not alter standard management based on QRISK3
- B. Arrange referral to sleep clinic for assessment of possible sleep apnoea before starting other interventions
- C. Delay statin therapy until sleep patterns improve as this may reduce his QRISK3 score below treatment threshold
- D. Recommend sleep hygiene measures but prioritise evidence-based interventions including statin therapy and lifestyle advice (Correct Answer)
- E. Prescribe zopiclone to improve sleep duration as this may provide greater cardiovascular benefit than statins
Explanation: ***Recommend sleep hygiene measures but prioritise evidence-based interventions including statin therapy and lifestyle advice*** - This patient has a **QRISK3 score of 16%**, which, according to **NICE guidelines**, indicates a high cardiovascular risk and warrants initiation of **statin therapy** (e.g., atorvastatin 20mg) for primary prevention. - While chronic sleep deprivation is an emerging risk factor, management should primarily focus on **evidence-based interventions** with proven efficacy in reducing **major adverse cardiovascular events (MACE)**, alongside lifestyle modifications and addressing sleep hygiene. *Sleep duration is not an established modifiable cardiovascular risk factor in current guidelines and should not alter standard management based on QRISK3* - While sleep duration is not formally integrated into **QRISK3** or most current official guidelines for pharmacological intervention thresholds, it is an increasingly recognized **non-traditional cardiovascular risk factor** that should be discussed as part of general lifestyle advice. - Disregarding poor sleep entirely misses an opportunity for **holistic patient care** and lifestyle modification, even if it doesn't directly alter the immediate statin decision. *Arrange referral to sleep clinic for assessment of possible sleep apnoea before starting other interventions* - The patient's poor sleep is primarily attributed to **night shifts** and reported poor sleep quality, not specific symptoms like loud snoring, witnessed apnoeas, or excessive daytime somnolence that would strongly suggest **sleep apnoea**. - Delaying **evidence-based interventions** like statin therapy for a patient with a **16% QRISK3 score** while awaiting a sleep clinic assessment would be inappropriate and increase their cardiovascular risk. *Delay statin therapy until sleep patterns improve as this may reduce his QRISK3 score below treatment threshold* - **Sleep duration** is not a parameter included in the **QRISK3 algorithm**, therefore, improvements in sleep patterns will not mathematically alter the calculated QRISK3 score. - Delaying **statin therapy** for a patient already at high cardiovascular risk (16%) based on an unproven effect on the risk score or an unvalidated intervention would be clinically unsound. *Prescribe zopiclone to improve sleep duration as this may provide greater cardiovascular benefit than statins* - **Zopiclone** and other hypnotics are indicated for short-term management of insomnia and have **no demonstrated cardiovascular benefits** that outweigh or even compare to statins. - Prescribing hypnotics carries risks such as **dependency, falls, and cognitive impairment**, making it an unsuitable primary intervention for cardiovascular risk reduction, especially over proven therapies.
Question 12: A 44-year-old woman attends requesting advice about breast screening. Her sister was recently diagnosed with breast cancer aged 47. Her mother had ovarian cancer aged 52 and died from it. The patient herself is well with no symptoms. She asks when she should start having mammograms. What is the most appropriate initial management?
- A. Arrange urgent referral to breast clinic for clinical assessment and mammography
- B. Refer to clinical genetics service for family history assessment and possible BRCA testing (Correct Answer)
- C. Reassure that she will be invited for routine NHS breast screening from age 50
- D. Arrange immediate bilateral mammography in primary care
- E. Arrange breast MRI surveillance to commence immediately
Explanation: ***Refer to clinical genetics service for family history assessment and possible BRCA testing*** - This patient has a significant family history featuring a first-degree relative with **breast cancer < 50** and another with **ovarian cancer**, suggesting a potential **BRCA1/BRCA2 mutation**. - Referral to **clinical genetics** or a specialist family history clinic is the correct primary care step to perform a formal **risk assessment** (e.g., using the Tyrer-Cuzick model) and determine eligibility for **genetic testing**. *Arrange urgent referral to breast clinic for clinical assessment and mammography* - Urgent referrals (2-week rule) are indicated for **symptomatic patients** (e.g., breast lumps, skin changes), but this patient is currently **asymptomatic**. - Diagnostic mammography in a symptomatic clinic is not the appropriate pathway for managing **asymptomatic hereditary risk**. *Reassure that she will be invited for routine NHS breast screening from age 50* - Routine screening starting at **age 50** is insufficient for patients at **high or moderate risk** due to family history, who may require surveillance starting as early as age 30 or 40. - Reassurance without formal risk assessment would be inappropriate given the **combination of breast and ovarian cancer** in her immediate family. *Arrange immediate bilateral mammography in primary care* - Primary care practitioners do not typically have the facility to direct-order **screening mammographies** outside of the national program or specialist referral scripts. - Mammography is less sensitive in **younger women** with denser breast tissue, making formal risk-stratified surveillance planning essential before ordering tests. *Arrange breast MRI surveillance to commence immediately* - **Breast MRI** is reserved for specific high-risk groups (like confirmed **BRCA mutation carriers**) and is not the first-line investigation in primary care. - Specialist surveillance schedules are determined by the **clinical genetics** or specialist team only after a comprehensive **pedigree analysis**.
Question 13: A 68-year-old man with a 4.7 cm infrarenal abdominal aortic aneurysm (AAA) detected through NHS screening attends for discussion. He has been under surveillance with 3-monthly scans for 18 months. The most recent scan shows the aneurysm has increased from 4.5 cm to 4.7 cm over the past 3 months. He is asymptomatic. He has COPD with FEV1 65% predicted, type 2 diabetes, and hypertension. He quit smoking 2 years ago. What is the most appropriate management?
- A. Continue 3-monthly ultrasound surveillance and refer if aneurysm reaches 5.5 cm (Correct Answer)
- B. Refer urgently to vascular surgery for consideration of elective repair
- C. Arrange CT angiography and refer to vascular surgery for discussion of repair options
- D. Increase surveillance frequency to monthly scans to closely monitor expansion rate
- E. Arrange MR angiography to assess suitability for endovascular repair
Explanation: ***Continue 3-monthly ultrasound surveillance and refer if aneurysm reaches 5.5 cm***- According to **NHS AAA screening guidelines**, an asymptomatic infrarenal aneurysm measuring **4.5-5.4 cm** is classified as a medium AAA, requiring **3-monthly ultrasound surveillance**.- Surgical referral is typically indicated when the aneurysm reaches **5.5 cm** in diameter, or if there is rapid expansion, defined as **>1 cm per year** or **>0.5 cm in 6 months**. The current growth of 0.2 cm in 3 months does not meet the rapid expansion criteria for immediate referral.*Refer urgently to vascular surgery for consideration of elective repair*- Urgent referral for elective repair is generally reserved for aneurysms that have reached the **5.5 cm threshold**, are **symptomatic**, or demonstrate **rapid expansion** significantly exceeding the current growth rate.- The patient's current aneurysm size of 4.7 cm and growth rate of 0.2 cm in 3 months (0.4 cm in 6 months) do not meet these criteria, as he remains **asymptomatic**.*Arrange CT angiography and refer to vascular surgery for discussion of repair options*- **CT angiography** is a detailed imaging modality primarily used for **pre-operative planning** and anatomical assessment once surgical intervention is being considered, typically after the 5.5 cm referral threshold is met.- For ongoing surveillance of stable, asymptomatic aneurysms below the surgical threshold, **ultrasound** is the standard, cost-effective, and **radiation-free** method.*Increase surveillance frequency to monthly scans to closely monitor expansion rate*- **National guidelines** for AAA surveillance recommend 3-monthly scans for aneurysms in the 4.5-5.4 cm range; **monthly scans** are not a standard surveillance interval.- Increasing scan frequency beyond established protocols offers no proven clinical benefit for a stable aneurysm and can lead to increased **healthcare burden** and unnecessary patient anxiety.*Arrange MR angiography to assess suitability for endovascular repair*- **MR angiography** (MRA), similar to CTA, provides detailed anatomical information for planning procedures like **EVAR (Endovascular Aneurysm Repair)**.- This is a step in the **surgical workup** and is premature when the patient has not yet met the size or growth criteria for surgical intervention.
Question 14: A 33-year-old woman attends with her cervical screening result showing hrHPV positive with low-grade dyskaryosis. She underwent colposcopy 6 months ago for similar results, and punch biopsy at that time showed CIN1. The colposcopist advised repeat cytology in 6 months, which is the current result. She has no symptoms and is currently 8 weeks pregnant. What is the most appropriate next step in management?
- A. Defer further investigation until after pregnancy and arrange colposcopy 3 months postpartum (Correct Answer)
- B. Arrange urgent colposcopy now to exclude high-grade disease
- C. Arrange large loop excision of transformation zone (LLETZ) after delivery
- D. Repeat cervical screening in 12 months
- E. Arrange repeat colposcopy and biopsy immediately
Explanation: ***Defer further investigation until after pregnancy and arrange colposcopy 3 months postpartum*** - In pregnant women with **CIN1** or **low-grade dyskaryosis**, the risk of progression to invasive cancer is extremely low, and further review should be delayed until the cervix has recovered from pregnancy-related changes. - **Colposcopy** and biopsies are generally avoided during pregnancy unless **invasive disease** is suspected, specifically to prevent complications like heavy bleeding due to increased **cervical vascularity**. *Arrange urgent colposcopy now to exclude high-grade disease* - Urgent colposcopy is only indicated in pregnancy if there is a suspicion of **malignancy** or **high-grade dyskaryosis** (e.g., severe dyskaryosis or suspicion of invasion). - **Low-grade dyskaryosis** with a known history of **CIN1** does not meet the criteria for urgent intervention during the first trimester. *Arrange large loop excision of transformation zone (LLETZ) after delivery* - **LLETZ** is a treatment for high-grade disease (**CIN2/3**) and is not typically indicated for **CIN1**, which has a high rate of **spontaneous regression**. - A follow-up **colposcopy** must be performed postpartum to reassess the status of the lesion before committing to any surgical treatment. *Repeat cervical screening in 12 months* - Repeating a smear in 12 months is inappropriate because the patient has persistent **low-grade changes** and **hrHPV positivity** following a previous abnormal biopsy. - **Colposcopic evaluation** is required after the 3-month postpartum period to ensure that the **CIN1** has not progressed or persisted. *Arrange repeat colposcopy and biopsy immediately* - Immediate referral for biopsy is unnecessary and poses risks of **bleeding** and **preterm labor** without providing any benefit for managing low-grade disease. - Clinical guidelines recommend waiting until at least **12 weeks postpartum** for repeat colposcopy to ensure accurate visualization and interpretation of the **transformation zone**.
Question 15: A 70-year-old woman attends for cardiovascular risk assessment. She has a BMI of 27 kg/m² and walks her dog daily for 30 minutes. She does not smoke and drinks 6 units of alcohol weekly. Blood tests show total cholesterol 6.8 mmol/L, HDL 1.6 mmol/L, and HbA1c 41 mmol/mol. Her BP is 126/76 mmHg. She asks about starting a statin as her friend was prescribed one. Her QRISK3 score is 8%. What is the most appropriate management?
- A. Prescribe atorvastatin 20 mg once daily and review lipids in 3 months
- B. Offer lifestyle advice about diet and exercise and reassess in 12 months (Correct Answer)
- C. Arrange lipid clinic referral for consideration of specialist lipid-lowering therapy
- D. Prescribe atorvastatin 80 mg once daily for primary prevention
- E. Request familial hypercholesterolaemia genetic testing
Explanation: ***Offer lifestyle advice about diet and exercise and reassess in 12 months*** - According to **NICE guidelines**, primary prevention with statins should be offered to individuals with a **QRISK3 score of 10% or higher** over 10 years; this patient's score is only **8%**. - The most appropriate initial step for a patient below the treatment threshold is reinforcing **lifestyle modifications** (diet and physical activity) and periodic monitoring. *Prescribe atorvastatin 20 mg once daily and review lipids in 3 months* - **Atorvastatin 20 mg** is a standard dose for primary prevention, but it is not indicated here as the patient's **10-year cardiovascular risk** (QRISK3 8%) is less than the **10% threshold** for statin initiation. - Routine pharmacological intervention is reserved for those who exceed the risk threshold or have specific high-risk comorbidities like **Type 1 Diabetes** or **Chronic Kidney Disease**, which this patient does not have. *Arrange lipid clinic referral for consideration of specialist lipid-lowering therapy* - Specialist referral is typically reserved for patients with **refractory hyperlipidemia**, suspected complex genetic disorders, or those who cannot tolerate standard therapy. - This patient does not meet the criteria for **specialist intervention** as her risk profile and lipid levels can be managed in a primary care setting. *Prescribe atorvastatin 80 mg once daily for primary prevention* - **Atorvastatin 80 mg** is a high-intensity dose used for **secondary prevention** in patients with established cardiovascular disease (e.g., post-MI or stroke) or very high primary prevention risk. - Using this dose for primary prevention in a low-risk (QRISK3 < 10%) patient is inappropriate and significantly increases the risk of **adverse effects** without clear benefit. *Request familial hypercholesterolaemia genetic testing* - Testing for **Familial Hypercholesterolaemia (FH)** is usually considered if total cholesterol is >7.5 mmol/L or if there is a suggestive **family history** of premature CVD, or clinical signs like **tendon xanthomata**. - This patient's total cholesterol of 6.8 mmol/L, while elevated, does not meet the typical **Simon Broome criteria** for immediate genetic testing without additional risk factors.
Question 16: A 56-year-old woman with type 2 diabetes for 12 years attends for annual review. Her HbA1c is 64 mmol/mol. She mentions she received a letter about diabetic eye screening but has not attended for the past 2 years as she has 'perfect vision' and sees no point in screening. Her visual acuity today is 6/6 bilaterally. What is the most important reason to emphasise the need for diabetic retinopathy screening?
- A. Diabetic retinopathy can progress to sight-threatening stages without visual symptoms (Correct Answer)
- B. Annual screening is a performance indicator that affects practice funding
- C. Proliferative retinopathy requires immediate pan-retinal photocoagulation to prevent blindness
- D. Visual acuity testing in general practice is insufficient to detect early retinopathy
- E. Patients with HbA1c >58 mmol/mol are at particularly high risk of rapid retinopathy progression
Explanation: ***Diabetic retinopathy can progress to sight-threatening stages without visual symptoms*** - Many early and even moderate stages of **diabetic retinopathy**, including **macular edema** or **pre-proliferative changes**, can be asymptomatic, with central vision remaining unaffected. - Screening allows for the **early detection** of these silent changes, enabling timely intervention (e.g., laser treatment, anti-VEGF injections) to prevent irreversible vision loss before symptoms manifest. *Annual screening is a performance indicator that affects practice funding* - While **Quality and Outcomes Framework (QOF)** or similar schemes link screening rates to practice funding, this is an administrative and financial reason, not a primary medical justification for the patient. - Emphasizing **financial incentives** rather than direct patient health outcomes is unethical and unlikely to improve long-term patient compliance. *Proliferative retinopathy requires immediate pan-retinal photocoagulation to prevent blindness* - **Pan-retinal photocoagulation (PRP)** is a critical treatment for **proliferative diabetic retinopathy** to prevent severe vision loss from neovascularization or vitreous hemorrhage. - However, the primary goal of screening is to identify retinopathy at **earlier, treatable stages** *before* it progresses to the sight-threatening, emergent proliferative stage requiring such intensive intervention. *Visual acuity testing in general practice is insufficient to detect early retinopathy* - **Visual acuity** primarily assesses **central macular function**; therefore, it can remain normal (6/6) even if significant **peripheral retinal damage** or early macular edema is present. - While technically true, this and other clinical facts are secondary to the main message that **asymptomatic progression** poses the greatest risk to the patient, highlighting the importance of comprehensive screening. *Patients with HbA1c >58 mmol/mol are at particularly high risk of rapid retinopathy progression* - An elevated **HbA1c** (like 64 mmol/mol in this patient) is indeed a significant **risk factor** for the development and progression of diabetic retinopathy due to poor glycemic control. - However, retinopathy can develop even in patients with seemingly **well-controlled diabetes** or at lower HbA1c levels, meaning screening is crucial for *all* diabetic patients, not just those with high HbA1c.
Question 17: A 61-year-old woman attends following her NHS bowel cancer screening. Her FIT result is 78 μg Hb/g faeces. She has no symptoms, no weight loss, and bowel habit is unchanged. Abdominal examination is normal. She has a history of diverticular disease diagnosed 3 years ago. She takes amlodipine for hypertension. What is the most appropriate next management step?
- A. Reassure and advise to complete another FIT test in 2 years
- B. Arrange urgent 2-week wait referral for suspected colorectal cancer (Correct Answer)
- C. Arrange routine colonoscopy via local colorectal service
- D. Request CT colonography
- E. Repeat FIT test in 3 months
Explanation: ***Arrange urgent 2-week wait referral for suspected colorectal cancer***- A **Faecal Immunochemical Test (FIT)** result of **78 μg Hb/g** faeces is significantly above the positive threshold (typically ≥10 μg Hb/g) in the NHS screening programme, mandating an **urgent 2-week wait (2WW) referral**.- The presence of **occult blood**, even without symptoms or a history of **diverticular disease**, means that colorectal cancer must be investigated promptly. *Reassure and advise to complete another FIT test in 2 years*- Reassurance is inappropriate as a **positive FIT result** indicates the presence of blood that needs urgent investigation to rule out serious pathology, including **colorectal cancer**.- Waiting for the next routine screening interval would constitute a significant and potentially harmful **diagnostic delay**. *Arrange routine colonoscopy via local colorectal service*- A **routine referral** is not appropriate for a patient with a positive bowel cancer screening result, which triggers the **suspected cancer pathway**.- NICE guidelines and screening protocols require an **urgent 2-week wait referral** to ensure timely investigation and diagnosis. *Request CT colonography*- The primary management step for the GP is to initiate the **formal 2WW referral** to a specialist colorectal service.- The specialist team will then determine the most appropriate diagnostic imaging or endoscopic procedure, with **colonoscopy** typically being the preferred initial investigation if suitable. *Repeat FIT test in 3 months*- Repeating a **positive FIT test** is contraindicated as it causes an unnecessary delay in investigation.- Tumor bleeding can be **intermittent**, meaning a repeat test could yield a false-negative result, further delaying a critical diagnosis.
Question 18: A 47-year-old man attends for advice about reducing his cardiovascular risk. He has a BMI of 32 kg/m², smokes 20 cigarettes daily, and drinks 28 units of alcohol weekly. His BP is 144/88 mmHg. His 10-year QRISK3 score is 18%. He is keen to make lifestyle changes but feels overwhelmed about where to start. Based on evidence for cardiovascular risk reduction, which intervention should be prioritised?
- A. Smoking cessation (Correct Answer)
- B. Weight reduction to achieve BMI <25 kg/m²
- C. Reduction of alcohol intake to <14 units per week
- D. Initiation of antihypertensive medication
- E. Increasing physical activity to 150 minutes per week
Explanation: ***Smoking cessation*** - **Smoking cessation** is the single most impactful intervention for reducing **cardiovascular risk**, as it significantly lowers the risk of **myocardial infarction** and stroke within a year of quitting. - It provides the most substantial and rapid **absolute risk reduction** compared to other lifestyle modifications, directly addressing the primary driver of atherosclerosis and improving endothelial function. *Weight reduction to achieve BMI <25 kg/m²* - While reducing **BMI** is crucial for long-term cardiovascular health, achieving a BMI <25 kg/m² from 32 kg/m² is a significant, long-term goal that may feel **overwhelming** to start with. - The relative benefit of **weight loss** on immediate cardiovascular outcomes, while important, is not as profound or rapid as the benefit seen from **smoking cessation**. *Reduction of alcohol intake to <14 units per week* - Reducing **alcohol intake** is important for overall health, including **blood pressure** control and reducing stroke risk, but its immediate impact on overall **cardiovascular mortality** is less pronounced than quitting smoking. - Excessive alcohol intake contributes to hypertension and cardiomyopathy, but the **effect size** of its reduction on the 10-year QRISK3 score is typically smaller than that of **smoking cessation**. *Initiation of antihypertensive medication* - While this patient's **blood pressure** of 144/88 mmHg and **QRISK3 score >10%** warrant consideration for medication, **lifestyle changes** are generally the first line of intervention, especially when the patient is motivated. - **Smoking cessation** itself can lead to improvements in blood pressure and vascular function, potentially postponing or reducing the need for immediate **pharmacological intervention**. *Increasing physical activity to 150 minutes per week* - Regular **physical activity** is a vital component of cardiovascular health, improving **lipid profiles** and blood pressure, but its individual impact on **absolute risk reduction** is less than that of quitting smoking. - Although exercise helps with **weight management** and overall well-being, prioritizing **smoking cessation** addresses the most potent and modifiable risk factor in this patient's profile.
Question 19: What is the screening interval for NHS breast screening for women aged 50-70 years in England?
- A. Annually
- B. Every 2 years
- C. Every 3 years (Correct Answer)
- D. Every 5 years
- E. Every 18 months
Explanation: ***Every 3 years*** - The **NHS Breast Screening Programme** currently invites women aged **50 to 70 years** for a screening **mammogram** once every three years. - This triennial interval is designed to balance the **early detection** of breast cancer with the potential harms of **over-diagnosis** and radiation exposure. *Annually* - **Annual screening** is not the standard for the general population in the UK as it increases the rate of **false positives** without significantly improving mortality outcomes. - Annual mammograms are typically reserved for specific **high-risk groups**, such as those with certain **genetic mutations** like BRCA1 or BRCA2. *Every 2 years* - While some international programs (such as those in the US or some European countries) use a **biennial** (two-year) interval, the **NHS model** remains strictly triennial. - Clinical evidence used by the NHS suggests that a **three-year gap** is sufficient for catching most slow-growing tumors in the target age group. *Every 5 years* - A **five-year interval** is considered too long, as it would likely lead to an increase in **interval cancers** (cancers appearing between screens) that are more advanced at diagnosis. - This frequency would significantly reduce the **sensitivity** of the screening program and fail to provide the necessary diagnostic benefit. *Every 18 months* - There is no clinical guideline within the **Public Health England** screening protocols that recommends an **18-month interval** for routine population screening. - Routine screening follows a **standardized schedule** to ensure efficient resource allocation and manageable **patient recall** systems.
Question 20: A 28-year-old woman attends with her cervical screening result. She is nulliparous and has been in a monogamous relationship for 2 years. The hrHPV test is positive, but cytology shows normal cells (hrHPV positive, cytology negative). She has no symptoms and examination is normal. She is anxious about the result and asks about the likelihood of developing cervical cancer. What is the most appropriate next management step?
- A. Repeat hrHPV test and cytology in 12 months (Correct Answer)
- B. Refer urgently to colposcopy under 2-week wait pathway
- C. Perform immediate colposcopy in primary care
- D. Repeat hrHPV test and cytology in 3 months
- E. Discharge back to routine 3-yearly screening
Explanation: ***Repeat hrHPV test and cytology in 12 months***- According to current screening guidelines, patients who are **hrHPV positive but cytology negative** should be invited for a repeat screen in **1 year** to allow for spontaneous viral clearance.- Most **HPV infections** in younger women are transient; immediate intervention is deferred because the risk of high-grade disease is low when cytology is normal.*Refer urgently to colposcopy under 2-week wait pathway*- An urgent **2-week wait** referral is reserved for clinical suspicion of **cervical cancer** on examination or severe cytological abnormalities.- Normal cytology with a first-time HPV positive result does not meet the criteria for urgent specialist referral.*Perform immediate colposcopy in primary care*- **Colposcopy** is a specialized procedure performed in a clinical setting by trained specialists, not as a routine **primary care** intervention.- Immediate referral for colposcopy is only indicated after a **positive cytology** result or if HPV persists for several years.*Repeat hrHPV test and cytology in 3 months*- A **3-month interval** is insufficient time for the immune system to clear the **hrHPV infection**, potentially leading to unnecessary anxiety and interventions.- The standard surveillance interval for persistent HPV with normal cytology is **12 months** to ensure clinically significant clearance can be detected.*Discharge back to routine 3-yearly screening*- Patients cannot be discharged to **routine recall** while they remain **hrHPV positive**, as they are at a higher risk of developing future neoplastic changes.- Routine screening is only appropriate if the sample is **HPV negative**, regardless of the cytological findings.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free